Table 2.
Cross tabulation assignment of high grade clear cell ovarian cancers and endometrioid ovarian cancers to the molecular subtypes (TCGA 6 clusters; CLOVAR 5 and 4 clusters) according to their FIGO stage (FIGO I/I versus III/IV) and grade (2 versus 3).
| FIGO Stage | Grade | |||||||
|---|---|---|---|---|---|---|---|---|
| I/II | III/IV | 2 | 3 | |||||
| N | 103 | 48 | 55 | P value |
29 | 74 | P value |
|
| TCGA 6* | Immunoreactive | 12 (100%) | 4 (33%) | 8 (67%) | 0.001 | 2 (17%) | 10 (83%) | 0.019 |
| Differentiated | 15 (100%) | 1 (7%) | 14 (93%) | 2 (13%) | 13 (87%) | |||
| Proliferative | 12 (100%) | 3 (25%) | 9 (75%) | 3 (25%) | 9 (75%) | |||
| Mesenchymal | 6 (100%) | 3 (50%) | 3 (50%) | 0 | 6 (100%) | |||
| Clear cell-like | 24 (100%) | 15 (62%) | 9 (38%) | 5 (21%) | 19 (79%) | |||
| Endometrioid-like | 34 (100%) | 22 (65%) | 12 (35%) | 17 (50%) | 17 (50%) | |||
| CLOVAR 5# | Immunoreactive | 15 (100%) | 3 (20%) | 12 (80%) | 0.001 | 1 (7%) | 14 (93%) | 0.022 |
| Differentiated | 19 (100%) | 6 (32%) | 13 (68%) | 4 (21%) | 15 (79%) | |||
| Proliferative | 15 (100%) | 4 (27%) | 11 (73%) | 4 (27%) | 11(73%) | |||
| Mesenchymal | 7 (100%) | 2 (29%) | 5 (71%) | 0 | 7 (100%) | |||
| Clear cell-like/Endometrioid-like | 47 (100%) | 33 (70%) | 14 (30%) | 20 (43%) | 27 (57%) | |||
| CLOVAR 4# | Immunoreactive | 18 (100%) | 5 (28%) | 13 (72%) | 0.037 | 1 (6%) | 17 (94%) | 0.005 |
| Differentiated | 56 (100%) | 33 (59%) | 23 (41%) | 23 (41%) | 33 (59%) | |||
| Proliferative | 20 (100%) | 8 (40%) | 12 (60%) | 5 (25%) | 15 (75%) | |||
| Mesenchymal | 9 (100%) | 2 (22%) | 7 (78%) | 0 | 9 (100%) | |||
*
Assignment using unsupervised clustering with the 1500 most differentially expressed genes described by the TCGA.
#
Assignment using unsupervised clustering with the reduced gene set CLOVAR genes described by Verhaak et al.